Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 540

Sort by

Sort Order Select

Journal Articles

Introduction to a review series on small-molecule targeted therapies for lymphoid malignancies

Andrew W. Roberts, Freda K. Stevenson

Blood (2021) 138 (13): 1089.

https://doi.org/10.1182/blood.2021012674

Published: 2021

Journal Articles

Targeting B-cell receptor and PI3K signaling in diffuse large B-cell lymphoma

Wendan Xu, Philipp Berning, Georg Lenz

Blood (2021) 138 (13): 1110–1119.

https://doi.org/10.1182/blood.2020006784

Published: 2021

Journal Articles

Synergistic efficacy of the dual PI3K-δ/γ inhibitor duvelisib with the Bcl-2 inhibitor venetoclax in Richter syndrome PDX models

Andrea Iannello, Nicoletta Vitale, Silvia Coma, Francesca Arruga, Amy Chadburn, Arianna Di Napoli, Carlo Laudanna, John N. Allan, Richard R. Furman, Jonathan A. Pachter, Silvia Deaglio, Tiziana Vaisitti

Blood (2021) 137 (24): 3378–3389.

https://doi.org/10.1182/blood.2020010187

Published: 2021

Includes: Supplemental data

Journal Articles

Increased activation of PI3 kinase-δ predisposes to B-cell lymphoma

Anne Durandy, Sven Kracker

Blood (2020) 135 (9): 638–643.

https://doi.org/10.1182/blood.2019002072

Published: 2020

Journal Articles

Analysis of Mechanisms Underlying Clonal Evolution of AML By a New Single-Cell Sequencing Platform

Ryosaku Inagaki, MSc, Masahiro Marshall Nakagawa, MD PhD, Yasuhito Nannya, MD PhD, Qi Xingxing, PhD, Lanying Zhao, MD, PhD, June Takeda, MD, Akinori Yoda, PhD, Ayana Kon, MD PhD, Hisashi Tsurumi, MD PhD, Hideki Makishima, MD PhD, Seishi Ogawa, MD PhD

Blood (2019) 134 (Supplement_1): 542.

https://doi.org/10.1182/blood-2019-126444

Published: 2019

Journal Articles

Single Chain Variable Fragment Linker Length Regulates CAR Biology and T Cell Efficacy

Blood (2019) 134 (Supplement_1): 247.

https://doi.org/10.1182/blood-2019-131024

Published: 2019

Journal Articles

MDSC Suppression of CAR T Cells Can be Reduced By Targeted Signaling Disruption

Estelle V Cervantes, Justin C. Boucher, PhD, Sae Bom Lee, Kristen Spitler, Kayla Reid, Marco L. Davila, MD PhD

Blood (2019) 134 (Supplement_1): 4438.

https://doi.org/10.1182/blood-2019-122752

Published: 2019

Journal Articles

Complement C3a Not C4a Activates Osteoclasts By Regulating the PI3K/PDK1/SGK3 Pathway in Patients with Multiple Myeloma

Rong Fu, Jr., PhD, Fengjuan Jiang, Hui Liu, Zhaoyun Liu, Siyang Yan, Jin Chen, Zonghong Shao, MD, Qing Shao

Blood (2019) 134 (Supplement_1): 4416.

https://doi.org/10.1182/blood-2019-127022

Published: 2019

Journal Articles

Ex Vivo Drug Sensitivity Screens Identify Personalized Treatment Options for CLL Patients

Sigrid Strand Skånland, PhD, Bendiksen Henrik, MSc, Andrea Cremaschi, PhD, Deepak Balaji Thimiri Govinda Raj, PhD, Ludvig Andre Munthe, MD PhD, Geir Erland Tjønnfjord, MD PhD, Kjetil Taskén, MD PhD

Blood (2019) 134 (Supplement_1): 5446.

https://doi.org/10.1182/blood-2019-121890

Published: 2019

Journal Articles

Targeting Sirt6 with OSS_128167 Displays Anti-Tumor Activities in Diffuse Large B-Cell Lymphoma through Down-Regulation of PI3K Signaling

Juan Yang, MM, Xiangxiang Zhou, MD, Ying Li, MD, Ya Zhang, MD, Xiaosheng Fang, MD, Na Chen, MD, Xin Wang, MD PhD

Blood (2019) 134 (Supplement_1): 5065.

https://doi.org/10.1182/blood-2019-127926

Published: 2019

Journal Articles

Prospective, Comprehensive Cardiac Assessment in Patients Receiving BTK Inhibitor Therapy

Chloe Pek Sang Tang, MBBS, FRACP, Andre La Gerche, Julie McMullen, BSc(Hons) PhDFCSANZ FAHA, Erin Howden, Sasanka M. Handunnetti, MBBS, FRACP, FRCPA, Isaac Goncalves, MBBS PhDFRACP, Jenny Ooi, Constantine S. Tam, MBBS (Hons), MD

Blood (2019) 134 (Supplement_1): 4301.

https://doi.org/10.1182/blood-2019-129808

Published: 2019

Journal Articles

Copanlisib, a PI3K Inhibitor, Demonstrates a Favorable Long-Term Safety Profile in a Pooled Analysis of Patients with Hematologic Malignancies

Pier Luigi Zinzani, MD, Armando Santoro, Luigina Mollica, MD FRCPC, PhD, Sirpa Leppä, MD PhD, George A Follows, MD PhD, Georg Lenz, MD, Won Seog Kim, MD PhD, Arnon Nagler, MD MSc, Panayiotis Panayiotidis, MD, Judit Demeter, MD PhD Dr. Sci, Franck Morschhauser, MD, Javier Munoz, MD MS, FACP, Ashok Miriyala, MD, Alice Benson, PhD, Jose Garcia-Vargas, MD, Barrett H Childs, MD, Martin Dreyling, MD

Blood (2019) 134 (Supplement_1): 4009.

https://doi.org/10.1182/blood-2019-131779

Published: 2019

Journal Articles

Results of a First in Human, Dose Ascending, Phase I Study Examining the Safety and Tolerability of KA2237, an Oral PI3K p110β/δ Inhibitor in Patients with Relapsed/Refractory (R/R) B-Cell Lymphoma

Loretta J. Nastoupil, MD MSc, Sattva S Neelapu, MD, Eric Davis, MD, Felipe Samaniego, MD, Nathan H Fowler, MD, Jason R. Westin, MD, Hun Ju Lee, Michael Wang, MD, Fredrick B. Hagemeister, MD, Philip Beer, MD PhD, Alexander R. L. Cecil, James Dow, Duncan McHale, Franck Silva, Penny Ward, Arash Yavari, Stephen Joseph Shuttleworth, PhD

Blood (2019) 134 (Supplement_1): 4099.

https://doi.org/10.1182/blood-2019-130401

Published: 2019

Journal Articles

Targeting PI3K and PLK1 to Overcome Ibrutinib-Venetoclax Resistance in Mantle Cell Lymphoma

Changying Jiang, PhD, Rongjia Zhang, Shaojun Zhang, PhD, William Lee, Shengjian Huang, PhD, Yang Liu, MD, Angela Leeming, Joseph Mitchell McIntosh, Preetesh Jain, MBBS,MDDM,PhD, Krystle Nomie, PhD, Linghua Wang, PhD, Michael L. Wang, MD

Blood (2019) 134 (Supplement_1): 4062.

https://doi.org/10.1182/blood-2019-128299

Published: 2019

Journal Articles

Final Results of Phase 1/1b Study of Tenalisib, Dual PI3K δ/γ Inhibitor in Patients with Relapsed/Refractory T-Cell Lymphoma

Swaminathan P. Iyer, MD, Brad M. Haverkos, MDMPH,MS, Jasmine Zain, MD, Radhakrishnan Ramchandren, MD, Mary Jo Lechowicz, MD, Sumana Devata, MD, Neil Korman, MD, Lauren C. Pinter-Brown, MD, Kasi Viswanath Routhu, PhD, Prajak Barde, MD, Ajit Mohanchandran Nair, PhD, Auris Huen, MD

Blood (2019) 134 (Supplement_1): 2831.

https://doi.org/10.1182/blood-2019-123954

Published: 2019

Journal Articles

Targeting Unique Synthetic Lethal Interactions between PI3K and MYC in B-ALL

Gang Xiao, PhD, Kohei Kume, PhD, Huimin Geng, PhD, Than Than Han, MS, Lars Klemm, MS, Markus Müschen, MD PhD

Blood (2019) 134 (Supplement_1): 3785.

https://doi.org/10.1182/blood-2019-128719

Published: 2019

Journal Articles

The Role of Decreased TIM-3 Expression of Natural Killer Cells in the Immune Pathogenesis of Severe Aplastic Anemia

Rong Fu, Jr., PhD, Shaoxue Ding, MD, Chunyan Liu, Bingnan Liu, Hui Liu, Liu Zhaoyun, Tong Chen, MD, Tian Zhang, Zonghong Shao, MD, Ting Wang

Blood (2019) 134 (Supplement_1): 3747.

https://doi.org/10.1182/blood-2019-127769

Published: 2019

Journal Articles

Class I PI3K Is Required for HSC Differentiation

Kristina Ames, PhD, Imit Kaur, PhD, Meng Tong, Shayda Hemmati, PhD, Ellen Tein, Shira Glushakow-Smith, Lindsay Gurska, Kira Gritsman, MD PhD

Blood (2019) 134 (Supplement_1): 2461.

https://doi.org/10.1182/blood-2019-123823

Published: 2019

Journal Articles

Establishing a Novel in Vitro Informed Precision Clinical Trial Pathway for Refractory Pediatric Leukemia

Chunfen Zhang, MD, Ritul Sharma, MSc., Thakur Satbir, PhD, Allison Cheney, Olena Vaske, PhD, Lauren Sanders, Jessica Boklan, MD, Victor A. Lewis, MD, Ronald Anderson, MDFRCPC, Olga Kovalchuk, MD, PhD, Norman J. Lacayo, MD, Aru Narendran, MD PhD, Kevin J. Bielamowicz, MD

Blood (2019) 134 (Supplement_1): 2633.

https://doi.org/10.1182/blood-2019-131444

Published: 2019

Journal Articles

Ifitm3 Is Essential for PI(3,4,5)P3-Dependent B-Cell Activation and Leukemogenesis

Jaewoong Lee, PhD, Gang Xiao, PhD, Kadriye Nehir Nehir Cosgun, PhD, Huimin Geng, PhD, Ning Ma, PhD, Lai N Chan, PhD, Kohei Kume, PhD, Matthew Nix, PhD, Zhengshan Chen, MD PhD, Chun-Wei David Chen, PhD, Jianjun Chen, PhD, Vishal Khairnar, PhD, Arun P. Wiita, MD PhD, Andrei Thomas-Tikhonenko, PhD, Michael Farzan, MD PhD, Michael S. Diamond, PhD, Jae U Jung, PhD, Nagarajan Vaidehi, PhD, Markus Müschen, MD PhD

Blood (2019) 134 (Supplement_1): 2782.

https://doi.org/10.1182/blood-2019-127615

Published: 2019

NARROW

Introduction to a review series on small-molecule targeted therapies for lymphoid malignancies

Targeting B-cell receptor and PI3K signaling in diffuse large B-cell lymphoma

Synergistic efficacy of the dual PI3K-δ/γ inhibitor duvelisib with the Bcl-2 inhibitor venetoclax in Richter syndrome PDX models

Increased activation of PI3 kinase-δ predisposes to B-cell lymphoma

Analysis of Mechanisms Underlying Clonal Evolution of AML By a New Single-Cell Sequencing Platform

Single Chain Variable Fragment Linker Length Regulates CAR Biology and T Cell Efficacy

MDSC Suppression of CAR T Cells Can be Reduced By Targeted Signaling Disruption

Complement C3a Not C4a Activates Osteoclasts By Regulating the PI3K/PDK1/SGK3 Pathway in Patients with Multiple Myeloma

Ex Vivo Drug Sensitivity Screens Identify Personalized Treatment Options for CLL Patients

Targeting Sirt6 with OSS_128167 Displays Anti-Tumor Activities in Diffuse Large B-Cell Lymphoma through Down-Regulation of PI3K Signaling

Prospective, Comprehensive Cardiac Assessment in Patients Receiving BTK Inhibitor Therapy

Copanlisib, a PI3K Inhibitor, Demonstrates a Favorable Long-Term Safety Profile in a Pooled Analysis of Patients with Hematologic Malignancies

Results of a First in Human, Dose Ascending, Phase I Study Examining the Safety and Tolerability of KA2237, an Oral PI3K p110β/δ Inhibitor in Patients with Relapsed/Refractory (R/R) B-Cell Lymphoma

Targeting PI3K and PLK1 to Overcome Ibrutinib-Venetoclax Resistance in Mantle Cell Lymphoma

Final Results of Phase 1/1b Study of Tenalisib, Dual PI3K δ/γ Inhibitor in Patients with Relapsed/Refractory T-Cell Lymphoma

Targeting Unique Synthetic Lethal Interactions between PI3K and MYC in B-ALL

The Role of Decreased TIM-3 Expression of Natural Killer Cells in the Immune Pathogenesis of Severe Aplastic Anemia

Class I PI3K Is Required for HSC Differentiation

Establishing a Novel in Vitro Informed Precision Clinical Trial Pathway for Refractory Pediatric Leukemia

Ifitm3 Is Essential for PI(3,4,5)P3-Dependent B-Cell Activation and Leukemogenesis

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only